| SCHEDULE OF RECONCILIATION OF PROFIT (LOSS) FROM SEGMENTS TO CONSOLIDATED |
The
following table presents reportable segment profit and loss, including significant expense categories, attributable to the Company’s
reportable segment for the periods presented:
SCHEDULE
OF RECONCILIATION OF PROFIT (LOSS) FROM SEGMENTS TO CONSOLIDATED
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
For The Three Months | | |
For The Six Months | |
| | |
Ended June 30, | | |
Ended June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
| | |
| | |
| | |
| |
| Revenue, net: | |
$ | 9,131 | | |
$ | 9,232 | | |
$ | 18,163 | | |
$ | 20,747 | |
| Less: | |
| | | |
| | | |
| | | |
| | |
| Cost of revenue: | |
| | | |
| | | |
| | | |
| | |
| Fixed | |
| 1,769 | | |
| 1,694 | | |
| 3,466 | | |
| 3,384 | |
| Variable | |
| 1,709 | | |
| 2,262 | | |
| 3,140 | | |
| 4,717 | |
| Operating and other expenses: | |
| | | |
| | | |
| | | |
| | |
| Sales and marketing | |
| 2,207 | | |
| 2,910 | | |
| 4,384 | | |
| 5,723 | |
| Research and development | |
| 149 | | |
| 173 | | |
| 301 | | |
| 350 | |
| General and administrative | |
| 2,976 | | |
| 2,661 | | |
| 5,427 | | |
| 5,211 | |
| Interest & other expense, net | |
| (9 | ) | |
| 65 | | |
| (18 | ) | |
| 123 | |
| Provision for income taxes | |
| 64 | | |
| - | | |
| 366 | | |
| 18 | |
| Segment net income (loss) | |
| 266 | | |
| (533 | ) | |
| 1,097 | | |
| 1,221 | |
| Reconciliation of profit or loss: | |
| | | |
| | | |
| | | |
| | |
| Loss on discontinued operations | |
| (108 | ) | |
| (107 | ) | |
| (218 | ) | |
| (214 | ) |
| Consolidated net income (loss) | |
$ | 158 | | |
$ | (640 | ) | |
$ | 879 | | |
$ | 1,007 | |
|
| SCHEDULE OF RECONCILIATION OF ADJUSTED EBITDA |
SCHEDULE
OF RECONCILIATION OF ADJUSTED EBITDA
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
Three Months Ended | | |
Six Months Ended | |
| | |
June 30, | | |
June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Income (loss) from continuing operations (GAAP Basis) | |
$ | 266 | | |
$ | (533 | ) | |
$ | 1,097 | | |
$ | 1,221 | |
| Depreciation and amortization | |
| 127 | | |
| 101 | | |
| 245 | | |
| 196 | |
| Stock-based compensation | |
| 4 | | |
| 9 | | |
| 8 | | |
| 24 | |
| Non-recurring legal expenses | |
| 65 | | |
| - | | |
| 380 | | |
| - | |
| Severance & related expense | |
| - | | |
| 524 | | |
| - | | |
| 692 | |
| Asset impairment - lab supplies | |
| - | | |
| 198 | | |
| - | | |
| 198 | |
| Lab supplies write-off | |
| 217 | | |
| - | | |
| 217 | | |
| - | |
| Taxes expense | |
| 64 | | |
| - | | |
| 366 | | |
| 18 | |
| Note payable interest | |
| - | | |
| 49 | | |
| - | | |
| 127 | |
| Other income/expense, net | |
| (9 | ) | |
| 10 | | |
| (18 | ) | |
| 14 | |
| Change in fair value of note payable | |
| - | | |
| 7 | | |
| - | | |
| (18 | ) |
| Adjusted EBITDA | |
$ | 734 | | |
$ | 365 | | |
$ | 2,295 | | |
$ | 2,472 | |
|